#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Stacking GLP-1 Drugs With Mood Peptides
Tirzepatide and retatrutide users sometimes add peptides like Semax for energy or mood. Here is what the trial evidence actually supports.
AGA MetALD Update: Where GLP-1 Drugs Stand
The AGA's new practice update addresses MetALD, a liver disease combining metabolic risk and alcohol use, and what it says about semaglutide.
Photos vs Self-Report: GLP-1 Accuracy
A University of Michigan study compared medication photos against self-reports for 322 GLP-1 users and found real gaps in compounded-drug reporting.
Semaglutide mechanism: the missing pieces
Semaglutide binds a well-mapped receptor, but a 2026 SELECT trial analysis shows weight loss explains only part of its heart benefit.
Semaglutide and Podocyte Senescence
Semaglutide cuts kidney disease events in trials. Researchers now ask whether slowing podocyte senescence in kidney filter cells explains part of why.
Semaglutide vs Older Diabetes Drugs
Semaglutide beats DPP-4 inhibitors like sitagliptin in trials, but head-to-head data against sulfonylureas and thiazolidinediones is thin.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.
GLP-1 Prescribing Without an Indication
A US records study of 92 million adults found GLP-1 prescribing without a documented indication rose 15-fold, and 35.1% of recipients had a normal BMI.
Semaglutide vs orforglipron: who paid?
A new indirect comparison says oral semaglutide beats orforglipron on weight loss. Five of its eight authors work for Novo Nordisk. Here is what it shows.
Orforglipron vs oral semaglutide in T2D
ACHIEVE-3 put the orforglipron pill head to head with the oral semaglutide pill in type 2 diabetes. Orforglipron won on HbA1c and lost on tolerability.
Semaglutide access and health inequity
Semaglutide works. Access does not follow need. Here is what fill-rate, pricing and policy data show about who actually gets treated, and who does not.
Semaglutide and wet AMD: signal vs proof
A 2026 study flagged semaglutide among five drugs with raised wet AMD reporting. Here is what that kind of signal can and cannot tell you.